Hostname: page-component-7b7567c8c-tnzcf Total loading time: 0 Render date: 2026-11-14T16:47:44.269Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine in practice: a prospective naturalistic study

Published online by Cambridge University Press:  02 January 2018

David Taylor,
Shameem Mir and
Shubra Mace
David Taylor*
Affiliation:
Maudsley Hospital, Denmark Hill London SE5 8AZ
Shameem Mir
Affiliation:
Maudsley Hospital, Denmark Hill London SE5 8AZ
Shubra Mace
Affiliation:
Maudsley Hospital, Denmark Hill London SE5 8AZ
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Aims and method

The study aimed to evaluate the effectiveness of the naturalistic use of olanzapine. Prescribers of olanzapine were asked to provide baseline and six-week Brief Psychiatric Rating Scale scores for 56 in-patients. Withdrawals from treatment were also noted.

Results

Olanzapine was not effective in any of the 12 patients with refractory schizophrenia and four patients worsened. In 36 patients with non-refractory schizophrenia, 16 (44%) improved and 10 (28%) were categorised as treatment failures. of eight patients with non-schizophrenic psychosis, only one improved and two were treatment failures.

Clinical implications

Olanzapine is effective in treating non-refractory schizophrenia, but appears to have no beneficial effect in refractory schizophrenia.

Information

Type
Drug Information Quarterly
Information
Psychiatric Bulletin , Volume 23 , Issue 3 , March 1999, pp. 178 - 180
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists

References

Baldacchino, A. M., Stubbs, J. H. & Nevison-Andrews, D. (1998) The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharmaceutical Journal 260, 207–209.Google Scholar
Beasley, C. M., Sanger, T., Satterlee, W., et al (1996) Olanzapine versus placebo: results of a double blind, fixed dose olanzapine trial. Psychopharmacology, 124, 159–167.Google Scholar
Conley, R. R., Tamminga, C. A., Bartko, J. J., et al (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry, 155, 914–920.Google Scholar
Kane, J., Hongfield, G., Singer, J., et al (1996) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle Scholar
Kerwin, R. & Taylor, D. (1996) New antipsychotics – a review of their current status and clinical potential. CNS Drugs, 6, 71–82.Google Scholar
Martin, J., Gomez, J. C., Garcia-Bernardo, E., et al (1997) Olanzapine in treatment-refractory schizophrenia: results of an open-label study. Journal of Clinical Psychiatry, 58, 479–483.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Pilowsky, L. S., Busatto, G. F., Taylor, M., et al (1996) Dopamine D2 receptor occupany in vivo by the novel antipsychotic olanzapine: 123I IBZM single photon emission topography (SPET) study. Psychopharmacology, 124, 148–153.Google Scholar
Tollefson, G. D., Beasley, C. M., Tran, P. V., et al (1996) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.Google Scholar
World Health Organization (1992) The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD–10). Geneva: WHO.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.